Hany Akeel Al-Hussaniy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hany Akeel Al-Hussaniy has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
Zahraa Salam Al-Tameemi
Dr. Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq
9 shared publicationsMeena Akeel Naji
Dr. Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq
8 shared publicationsAmjad I. Oraibi
Department of Pharmacy, Al-Manara College for Medical Sciences University, Misan, Iraq
7 shared publicationsAli Hikmat Alburghaif
Department of Pharmaceutical Chemistry, Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq
6 shared publicationsZahraa S. Al-Tameemi
Department of Pharmacy, Bilad Alrafidain University College, Diyala Junction, Baqubah, Diyala
5 shared publications- Ali Hikmat Alburghaif
Department of Pharmaceutical Chemistry, Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq
4 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Pensoft Publishers in Folia Medica
- Vol. 68 (5) , e185886
Monitoring adverse drug reactions of isotretinoin: a prospective observational study
Introduction : Acne vulgaris is very common and may have a significant psychosocial effect. Moderate to severe acne is best treated using oral isotretinoin, which has a wide spectrum of adverse drug reactions (ADRs). Aim : To characterize the occurrence, pattern, and severity of isotretinoin-related ADRs in the Iraqi dermatology clinics and clarify clinical and treatment factors linked to its frequency. Patients and methods : This was a prospective observational cohort study carried out at two of the outpatient dermatology clinics in Basra city between January 2024 and December 2025. Patients were recruited consecutively as they were aged 12 years and older and had been taking systemic isotretinoin as the main form of therapy against acne. Results : Out of 420 patients who were screened, 400 patients qualified. The mean age was 21.8 years, and the SD was 4.7 years; 55% of the population was female, and 90% had moderate or severe acne. In general, 360 patients (90%) had at least one ADR, which led to 965 events. The most common were mucocutaneous reactions (88.5% of patients); then there were laboratory abnormalities (22%) and musculoskeletal complaints (around 15%-16%). Biochemical abnormalities were generally mild to moderate, while clinically significant psychiatric events were rare. Moderate/severe ADRs were independently related to female sex, baseline dyslipidemia, and daily dose ≥0.5 mg/kg/day. Conclusion : With the aid of organized monitoring, risk-specific dosing, and strong pregnancy prevention and counseling measures, isotretinoin may be deployed effectively and in a relatively safe way in the Iraqi dermatology clinics.
- 30 October 2026
- Published by Pensoft Publishers in Folia Medica
- Vol. 68 (5) , e185886
Open AccessMonitoring adverse drug reactions of isotretinoin: a prospective observational study
Introduction : Acne vulgaris is very common and may have a significant psychosocial effect. Moderate to severe acne is best treated using oral isotretinoin, which has a wide spectrum of adverse drug reactions (ADRs). Aim : To characterize the occurrence, pattern, and severity of isotretinoin-related ADRs in the Iraqi dermatology clinics and clarify clinical and treatment factors linked to its frequency. Patients and methods : This was a prospective observational cohort study carried out at two of the outpatient dermatology clinics in Basra city between January 2024 and December 2025. Patients were recruited consecutively as they were aged 12 years and older and had been taking systemic isotretinoin as the main form of therapy against acne. Results : Out of 420 patients who were screened, 400 patients qualified. The mean age was 21.8 years, and the SD was 4.7 years; 55% of the population was female, and 90% had moderate or severe acne. In general, 360 patients (90%) had at least one ADR, which led to 965 events. The most common were mucocutaneous reactions (88.5% of patients); then there were laboratory abnormalities (22%) and musculoskeletal complaints (around 15%-16%). Biochemical abnormalities were generally mild to moderate, while clinically significant psychiatric events were rare. Moderate/severe ADRs were independently related to female sex, baseline dyslipidemia, and daily dose ≥0.5 mg/kg/day. Conclusion : With the aid of organized monitoring, risk-specific dosing, and strong pregnancy prevention and counseling measures, isotretinoin may be deployed effectively and in a relatively safe way in the Iraqi dermatology clinics.
- Open Access
- 24 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9494
β-Sitosterol–Naringenin Co-Loaded Nanophytosomes: Encapsulation, Compound-Specific Release Kinetics, Machine Learning-Assisted Release Prediction, and Cell-Dependent Anticancer Activity
β-Sitosterol and naringenin have anticancer potential but poor biopharmaceutical properties, while their behavior when co-encapsulated remains poorly defined. This study examined whether co-loading alters encapsulation efficiency, compound-specific release behavior, predictability, and cell-dependent activity. Single- and co-loaded nanophytosomes were characterized for encapsulation and release. Release profiles underwent comparative kinetic modelling, uncertainty-aware augmentation, early-to-late ridge-regression forecasting, Weibull-parameter reconstruction, and exploratory reconstructed-replicate holdout assessment. Cytotoxicity was assessed in A549 (ATCC CCL-185), HCT116 (ATCC CCL-247), and HEK293 (ATCC CRL-1573) cells, with docking against MEK1, COX-2, and PI3Kα. Co-loading increased β-sitosterol encapsulation from 5.92% to 66.61% but reduced naringenin encapsulation from 89.76% to 40.40% (p = 0.02), the co-loaded formulation also exhibited the smallest vesicles (132.7 ± 3.2 nm). At 48 h, release reached 87.30% and 73.24%, respectively; Weibull best described β-sitosterol and Higuchi naringenin, revealing asynchronous release and a time-dependent delivery ratio. Across 1200 augmented profiles, first-4-h measurements predicted 6–48-h release with R2 = 0.976–0.996, while parameter-based reconstruction reproduced compound-specific trajectories. Exploratory reconstructed-replicate assessment yielded a pooled R2 of 0.938 (mean absolute error (MAE) = 3.32%; root-mean-square error (RMSE) = 4.78%). The co-loaded formulation showed its strongest relative activity in A549 cells and better preserved HEK293 viability than the free combination, whereas the free combination was more active in HCT116 cells. Naringenin docked across all targets (7.58 to −8.40 kcal/mol), whereas β-sitosterol showed weaker binding and no COX-2 pose. Co-loading was associated with opposing encapsulation trends, while the resulting formulation exhibited compound-specific release kinetics and cell-dependent responses rather than uniformly enhanced activity. Integrating physicochemical characterization, kinetic discrimination, predictive modelling, docking, and cell testing provides a multidimensional framework for dual-bioactive nanophytosomes.
- 24 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9494
Open Accessβ-Sitosterol–Naringenin Co-Loaded Nanophytosomes: Encapsulation, Compound-Specific Release Kinetics, Machine Learning-Assisted Release Prediction, and Cell-Dependent Anticancer Activity
β-Sitosterol and naringenin have anticancer potential but poor biopharmaceutical properties, while their behavior when co-encapsulated remains poorly defined. This study examined whether co-loading alters encapsulation efficiency, compound-specific release behavior, predictability, and cell-dependent activity. Single- and co-loaded nanophytosomes were characterized for encapsulation and release. Release profiles underwent comparative kinetic modelling, uncertainty-aware augmentation, early-to-late ridge-regression forecasting, Weibull-parameter reconstruction, and exploratory reconstructed-replicate holdout assessment. Cytotoxicity was assessed in A549 (ATCC CCL-185), HCT116 (ATCC CCL-247), and HEK293 (ATCC CRL-1573) cells, with docking against MEK1, COX-2, and PI3Kα. Co-loading increased β-sitosterol encapsulation from 5.92% to 66.61% but reduced naringenin encapsulation from 89.76% to 40.40% (p = 0.02), the co-loaded formulation also exhibited the smallest vesicles (132.7 ± 3.2 nm). At 48 h, release reached 87.30% and 73.24%, respectively; Weibull best described β-sitosterol and Higuchi naringenin, revealing asynchronous release and a time-dependent delivery ratio. Across 1200 augmented profiles, first-4-h measurements predicted 6–48-h release with R2 = 0.976–0.996, while parameter-based reconstruction reproduced compound-specific trajectories. Exploratory reconstructed-replicate assessment yielded a pooled R2 of 0.938 (mean absolute error (MAE) = 3.32%; root-mean-square error (RMSE) = 4.78%). The co-loaded formulation showed its strongest relative activity in A549 cells and better preserved HEK293 viability than the free combination, whereas the free combination was more active in HCT116 cells. Naringenin docked across all targets (7.58 to −8.40 kcal/mol), whereas β-sitosterol showed weaker binding and no COX-2 pose. Co-loading was associated with opposing encapsulation trends, while the resulting formulation exhibited compound-specific release kinetics and cell-dependent responses rather than uniformly enhanced activity. Integrating physicochemical characterization, kinetic discrimination, predictive modelling, docking, and cell testing provides a multidimensional framework for dual-bioactive nanophytosomes.
- Open Access
- 11 September 2026
- Published by Universidad Nacional de Colombia in Revista Colombiana de Ciencias Químico Farmacéuticas
- Vol. 55 (3) , 903-916
Next-generation nanomedicine: Bridging tumor biology with individualized drug delivery
Introduction: Nanomedicine has made a significant impact in the field of oncology, with many nanosized systems reaching the market and clinical trials. These novel drug delivery systems often respond to biological triggers and temporarily target tissues, enhancing the therapeutic index of chemotherapeutics. Despite these advances, including stimuli-responsive and targeting ligand-decorated nanosystems, the therapeutic results have not yet fulfilled expectations. Objective: To explore the concept of smart nanodrug delivery systems designed for personalized oncology, focusing on how personalization can be integrated into the design, fabrication, and clinical translation of nanocarriers. Methods: A personalized approach encompasses tumor characterization and patient-specific profile analysis, resulting in predictive models that establish individual dosing regimens and predict therapeutic outcomes. Companion diagnostics allow monitoring of the tumor response to treatment and the modulation of dosing depending on therapeutic efficacy. Data were obtained from current literature describing tumor profiling, predictive modeling, and smart nanocarrier systems responding to biological or physical stimuli. Results: Smart nanocarriers integrate stimuli-responsive features and targeting moieties to exploit the tumor microenvironment. The application of these systems can be combined with predictive modeling and companion diagnostics to optimize therapy in real time. Preclinical investigations confirm that such systems enhance tumor targeting, improve drug bioavailability, and reduce systemic toxicity. The transition from design and fabrication to clinical translation involves validation of pharmacokinetics, biodistribution, and toxicity. Conclusion: The synergistic incorporation of multiple smart functionalities in nanocarriers for drug delivery in oncology provides a foundation for personalized medicine. Personalized dosing applications, predictive modeling, and companion diagnostics enable tailored therapeutic outcomes, reduced toxicity, and improved patient survival. The translation of smart nanocarrier platforms into clinical practice represents a crucial step toward personalized oncology.
- 11 September 2026
- Published by Universidad Nacional de Colombia in Revista Colombiana de Ciencias Químico Farmacéuticas
- Vol. 55 (3) , 903-916
Open AccessNext-generation nanomedicine: Bridging tumor biology with individualized drug delivery
Introduction: Nanomedicine has made a significant impact in the field of oncology, with many nanosized systems reaching the market and clinical trials. These novel drug delivery systems often respond to biological triggers and temporarily target tissues, enhancing the therapeutic index of chemotherapeutics. Despite these advances, including stimuli-responsive and targeting ligand-decorated nanosystems, the therapeutic results have not yet fulfilled expectations. Objective: To explore the concept of smart nanodrug delivery systems designed for personalized oncology, focusing on how personalization can be integrated into the design, fabrication, and clinical translation of nanocarriers. Methods: A personalized approach encompasses tumor characterization and patient-specific profile analysis, resulting in predictive models that establish individual dosing regimens and predict therapeutic outcomes. Companion diagnostics allow monitoring of the tumor response to treatment and the modulation of dosing depending on therapeutic efficacy. Data were obtained from current literature describing tumor profiling, predictive modeling, and smart nanocarrier systems responding to biological or physical stimuli. Results: Smart nanocarriers integrate stimuli-responsive features and targeting moieties to exploit the tumor microenvironment. The application of these systems can be combined with predictive modeling and companion diagnostics to optimize therapy in real time. Preclinical investigations confirm that such systems enhance tumor targeting, improve drug bioavailability, and reduce systemic toxicity. The transition from design and fabrication to clinical translation involves validation of pharmacokinetics, biodistribution, and toxicity. Conclusion: The synergistic incorporation of multiple smart functionalities in nanocarriers for drug delivery in oncology provides a foundation for personalized medicine. Personalized dosing applications, predictive modeling, and companion diagnostics enable tailored therapeutic outcomes, reduced toxicity, and improved patient survival. The translation of smart nanocarrier platforms into clinical practice represents a crucial step toward personalized oncology.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of Education and Health Promotion
- Vol. 15 (1)
From knowledge to practice: The impact of leaflet-supported education on exclusive breastfeeding in Iraqi mothers
BACKGROUND: Exclusive breastfeeding is a cornerstone of neonatal survival, yet rates in Iraq remain below international targets. Low-cost educational interventions may provide a feasible way to improve maternal knowledge and practice. To evaluate the effect of leaflet-based education on mothers, attitudes, and exclusive breastfeeding practices among pregnant women in Iraq. This study aimed to evaluate the effect of leaflet-based education on maternal knowledge, attitudes, and exclusive breastfeeding practices among pregnant women in Iraq MATERIALS AND METHODS: A simple randomized study was conducted at Al-Karama Teaching Hospital, Baghdad, involving 90 third-trimester pregnant women. Participants were randomly assigned to an intervention group ( n = 45) receiving education with both a leaflet and the MCH book, or a control group ( n = 45) receiving education with the MCH book alone. Knowledge and attitude scores were assessed pre- and post-intervention. RESULTS: The knowledge scores improved significantly in both groups, with a greater percentage increase in the intervention group (+34.5%) compared to the negative group (+26.9%). Attitude scores also increased significantly in both groups, with a trend toward stronger improvement in the intervention arm (+17.5% vs. +13.5%). Exclusive breastfeeding rates at one month postpartum were markedly higher in the intervention group (57.8%) compared with the control group (20.0%). Logistic regression identified group assignment as the strongest independent predictor (OR = 4.6, 95% CI: 1.8–11.5, P = 0.002), while maternal education also showed a significant effect (OR = 2.1, 95% CI: 1.0–4.7, P = 0.048). CONCLUSION: Leaflet-based education, when combined with the MCH book, significantly improved exclusive breastfeeding practices and showed positive, though not statistically significant, trends in enhancing maternal knowledge and attitudes.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of Education and Health Promotion
- Vol. 15 (1)
Open AccessFrom knowledge to practice: The impact of leaflet-supported education on exclusive breastfeeding in Iraqi mothers
BACKGROUND: Exclusive breastfeeding is a cornerstone of neonatal survival, yet rates in Iraq remain below international targets. Low-cost educational interventions may provide a feasible way to improve maternal knowledge and practice. To evaluate the effect of leaflet-based education on mothers, attitudes, and exclusive breastfeeding practices among pregnant women in Iraq. This study aimed to evaluate the effect of leaflet-based education on maternal knowledge, attitudes, and exclusive breastfeeding practices among pregnant women in Iraq MATERIALS AND METHODS: A simple randomized study was conducted at Al-Karama Teaching Hospital, Baghdad, involving 90 third-trimester pregnant women. Participants were randomly assigned to an intervention group ( n = 45) receiving education with both a leaflet and the MCH book, or a control group ( n = 45) receiving education with the MCH book alone. Knowledge and attitude scores were assessed pre- and post-intervention. RESULTS: The knowledge scores improved significantly in both groups, with a greater percentage increase in the intervention group (+34.5%) compared to the negative group (+26.9%). Attitude scores also increased significantly in both groups, with a trend toward stronger improvement in the intervention arm (+17.5% vs. +13.5%). Exclusive breastfeeding rates at one month postpartum were markedly higher in the intervention group (57.8%) compared with the control group (20.0%). Logistic regression identified group assignment as the strongest independent predictor (OR = 4.6, 95% CI: 1.8–11.5, P = 0.002), while maternal education also showed a significant effect (OR = 2.1, 95% CI: 1.0–4.7, P = 0.048). CONCLUSION: Leaflet-based education, when combined with the MCH book, significantly improved exclusive breastfeeding practices and showed positive, though not statistically significant, trends in enhancing maternal knowledge and attitudes.
- 22 August 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24, 1-11
Pregabalin: A Multifunctional Modulator in Neuropathic Pain and Beyond
Introduction: Pregabalin is a structural analogue of γ-aminobutyric acid (GABA) that functions as a potent modulator of excitatory neurotransmission through high-affinity binding to the α2δ subunit of voltage-gated calcium channels. This review provides a comprehensive overview of its pharmacological properties, clinical efficacy, and therapeutic scope across neuropathic and non-neuropathic conditions. Method: This review is a narrative, descriptive, and integrative type of review conducted using current evidence regarding pharmacology, therapeutic applications, comparative efficacy, and pregabalin safety profile. Results: Pregabalin exhibits rapid absorption, high bioavailability, linear pharmacokinetics, renal elimination, and minimal hepatic metabolism, supporting predictable dosing. Clinically, it demonstrates proven efficacy in neuropathic pain syndromes, including diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and spinal cord injury-related pain, where it acts as a first-line or adjunctive agent. Beyond analgesia, pregabalin serves as an adjunct in partial seizures, a recognized treatment for generalized anxiety disorder, and an emerging option for sleep disturbances and comorbid psychiatric conditions. Comparative analyses indicate similar or superior efficacy to gabapentin and other first-line agents, with added benefit in improving sleep and global function. Adverse effects such as dizziness, somnolence, and peripheral edema are generally mild and dose-related. Discussion: Future studies should clarify its role in treatment-resistant pain, psychiatric comorbidities, and sleep-related disorders to optimize its clinical use. Conclusion: Owing to its favorable safety profile, limited drug-drug interactions, and broad therapeutic potential, pregabalin remains an essential component of neuropathic pain.
- 22 August 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24, 1-11
Pregabalin: A Multifunctional Modulator in Neuropathic Pain and Beyond
Introduction: Pregabalin is a structural analogue of γ-aminobutyric acid (GABA) that functions as a potent modulator of excitatory neurotransmission through high-affinity binding to the α2δ subunit of voltage-gated calcium channels. This review provides a comprehensive overview of its pharmacological properties, clinical efficacy, and therapeutic scope across neuropathic and non-neuropathic conditions. Method: This review is a narrative, descriptive, and integrative type of review conducted using current evidence regarding pharmacology, therapeutic applications, comparative efficacy, and pregabalin safety profile. Results: Pregabalin exhibits rapid absorption, high bioavailability, linear pharmacokinetics, renal elimination, and minimal hepatic metabolism, supporting predictable dosing. Clinically, it demonstrates proven efficacy in neuropathic pain syndromes, including diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and spinal cord injury-related pain, where it acts as a first-line or adjunctive agent. Beyond analgesia, pregabalin serves as an adjunct in partial seizures, a recognized treatment for generalized anxiety disorder, and an emerging option for sleep disturbances and comorbid psychiatric conditions. Comparative analyses indicate similar or superior efficacy to gabapentin and other first-line agents, with added benefit in improving sleep and global function. Adverse effects such as dizziness, somnolence, and peripheral edema are generally mild and dose-related. Discussion: Future studies should clarify its role in treatment-resistant pain, psychiatric comorbidities, and sleep-related disorders to optimize its clinical use. Conclusion: Owing to its favorable safety profile, limited drug-drug interactions, and broad therapeutic potential, pregabalin remains an essential component of neuropathic pain.
- Open Access
- 18 August 2026
- Published by Bentham Science Publishers Ltd. in The Open Public Health Journal
- Vol. 19 (1)
Assessment of Lifestyle Habits and Health-related Behaviors among University Students in Iraq: Evidence from Bilad Al-Rafidain University College
Introduction: University students experience various lifestyle factors that influence their behavioral, physical, and psychological well-being. Understanding lifestyle patterns among students is essential for designing effective programs to promote health in our country, Iraq. Limited data exist regarding lifestyle behaviors among students in pharmacy and related health sciences. Objectives: This study examined lifestyle habits and health-related behaviors among students at an Iraqi university and identified associations among physical activity, smoking, stress, dietary habits, and body weight status. Method: This cross-sectional descriptive analytical study was conducted. A sample of 250 students was randomly selected from the study population during the academic year 2022–2023. Result: The research showed that participants who performed physical activity constituted a higher percentage than those who did not (38.4%). The majority of them walked daily for 1–2 hours (31.2%) as their main means of transportation, while the highest percentage preferred to meet their needs by car (59.6%). Those who slept less than 6 hours a day constituted the majority (30.4%) of this group. Nonsmokers constituted 80.4% of the participants. Among smokers, most used electronic cigarettes (38.8%). Students suffering from stress constituted 80.4%, with studying being the main source of stress (41.2%). Smoking was significantly associated with stress in this age group (x 2 = 3.98, p = 0.046). Students who were committed to measuring their weight represented 68%, those who regularly ate meals represented 42%, those who consumed fast food represented 58.8%, and 64% were committed to drinking water daily. A strong association was found between fast food consumption and non-ideal body weight (x 2 = 13.09, p -value = 0.0003), indicating that students with non-ideal body weight were more likely to consume fast food. Discussion: The article shows that many students do not engage in sufficient physical activity and that sleep problems are common among them. A large number of students sleep fewer than six hours a night, underscoring the need for universities in Iraq to adopt programs that encourage physical activity, promote health and nutrition, and support stress management. Conclusion: The study reveals several noteworthy findings regarding physical activity, transportation preferences, sleep patterns, smoking habits, stress levels, body weight awareness, and nutritional habits among students.
- 18 August 2026
- Published by Bentham Science Publishers Ltd. in The Open Public Health Journal
- Vol. 19 (1)
Open AccessAssessment of Lifestyle Habits and Health-related Behaviors among University Students in Iraq: Evidence from Bilad Al-Rafidain University College
Introduction: University students experience various lifestyle factors that influence their behavioral, physical, and psychological well-being. Understanding lifestyle patterns among students is essential for designing effective programs to promote health in our country, Iraq. Limited data exist regarding lifestyle behaviors among students in pharmacy and related health sciences. Objectives: This study examined lifestyle habits and health-related behaviors among students at an Iraqi university and identified associations among physical activity, smoking, stress, dietary habits, and body weight status. Method: This cross-sectional descriptive analytical study was conducted. A sample of 250 students was randomly selected from the study population during the academic year 2022–2023. Result: The research showed that participants who performed physical activity constituted a higher percentage than those who did not (38.4%). The majority of them walked daily for 1–2 hours (31.2%) as their main means of transportation, while the highest percentage preferred to meet their needs by car (59.6%). Those who slept less than 6 hours a day constituted the majority (30.4%) of this group. Nonsmokers constituted 80.4% of the participants. Among smokers, most used electronic cigarettes (38.8%). Students suffering from stress constituted 80.4%, with studying being the main source of stress (41.2%). Smoking was significantly associated with stress in this age group (x 2 = 3.98, p = 0.046). Students who were committed to measuring their weight represented 68%, those who regularly ate meals represented 42%, those who consumed fast food represented 58.8%, and 64% were committed to drinking water daily. A strong association was found between fast food consumption and non-ideal body weight (x 2 = 13.09, p -value = 0.0003), indicating that students with non-ideal body weight were more likely to consume fast food. Discussion: The article shows that many students do not engage in sufficient physical activity and that sleep problems are common among them. A large number of students sleep fewer than six hours a night, underscoring the need for universities in Iraq to adopt programs that encourage physical activity, promote health and nutrition, and support stress management. Conclusion: The study reveals several noteworthy findings regarding physical activity, transportation preferences, sleep patterns, smoking habits, stress levels, body weight awareness, and nutritional habits among students.
- Open Access
- 9 June 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 15 (2) , 115247
Letter to the Editor: Bridging the immunization gap in pediatric autoimmune disorders - insights from inflammatory bowel disease and vaccine response patterns
Autoimmune diseases represent serious conditions characterized by immune dysregulation, which compromises the body’s defense mechanisms and affects responses to infections and Vaccines. In addition to this, the treatment of these diseases involves mostly immunosuppressant’s. I read with great interest the study published in the World Journal of Clinical Pediatrics by Makarova et al , examining vaccines and antibody levels in children with inflammatory bowel disease (IBD), with a focus on enhancing children’s immune responses. Children with autoimmune diseases often show poor response to vaccines, which is attributed to their health condition and the immunosuppressive drugs used in treatment. One of the effective ways to protect these people in general and the children in specific is to follow personalized vaccination plans, or as mentioned in the research being discussed, to carry out revaccination and conduct serology tests and immunoglobulin G to ensure the effectiveness of vaccination plans. Those with diseases similar to IBD, and related diseases should conduct periodic checks after vaccination.
- 9 June 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 15 (2) , 115247
Open AccessLetter to the Editor: Bridging the immunization gap in pediatric autoimmune disorders - insights from inflammatory bowel disease and vaccine response patterns
Autoimmune diseases represent serious conditions characterized by immune dysregulation, which compromises the body’s defense mechanisms and affects responses to infections and Vaccines. In addition to this, the treatment of these diseases involves mostly immunosuppressant’s. I read with great interest the study published in the World Journal of Clinical Pediatrics by Makarova et al , examining vaccines and antibody levels in children with inflammatory bowel disease (IBD), with a focus on enhancing children’s immune responses. Children with autoimmune diseases often show poor response to vaccines, which is attributed to their health condition and the immunosuppressive drugs used in treatment. One of the effective ways to protect these people in general and the children in specific is to follow personalized vaccination plans, or as mentioned in the research being discussed, to carry out revaccination and conduct serology tests and immunoglobulin G to ensure the effectiveness of vaccination plans. Those with diseases similar to IBD, and related diseases should conduct periodic checks after vaccination.
- Open Access
- 21 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Precision dosing in neonates: AI as a pharmacological tool
The pharmacological therapy of neonates is extremely complicated due to the immature organ systems of the body, high water content, and low number of clinical studies in children of this age. Conventional dosing strategies, usually based on weight or age, are often inaccurate and may result in either underexposure or toxicity. A structured literature search was performed in PubMed/MEDLINE and Scopus, as well as Web of Science, from 2000 to September 2025. The search was based on neonatal pharmacokinetics, model-informed precision dosing (MIPD), Bayesian dosing, and artificial intelligence/machine learning. Following the removal of duplicates and two-stage screening (title/abstract and full-text review), 82 studies were used in the end to conduct this review. This review follows the PRISMA 2020 flow selection style. Pharmacokinetic and pharmacodynamic (popPK/PD) models, with the help of Bayesian strategies, can offer a context for therapy individualization, but they are still limited by the absence of complete information and high intersubjective differences. Artificial intelligence (AI) can also be used to provide an extra level of support by processing vast and multifaceted data, discovering latent trends, and improving dose predictions in real time. This review concluded that applications of AI-driven tools are now emerging in neonatal intensive care, particularly for antibiotics and analgesics, where accurate dosing is critical. Combining AI with known pharmacometric practices could assist clinicians in minimizing adverse drug reactions, enhancing treatment outcomes, and getting closer to actual personalized pharmacotherapy in neonates.
- 21 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Open AccessPrecision dosing in neonates: AI as a pharmacological tool
The pharmacological therapy of neonates is extremely complicated due to the immature organ systems of the body, high water content, and low number of clinical studies in children of this age. Conventional dosing strategies, usually based on weight or age, are often inaccurate and may result in either underexposure or toxicity. A structured literature search was performed in PubMed/MEDLINE and Scopus, as well as Web of Science, from 2000 to September 2025. The search was based on neonatal pharmacokinetics, model-informed precision dosing (MIPD), Bayesian dosing, and artificial intelligence/machine learning. Following the removal of duplicates and two-stage screening (title/abstract and full-text review), 82 studies were used in the end to conduct this review. This review follows the PRISMA 2020 flow selection style. Pharmacokinetic and pharmacodynamic (popPK/PD) models, with the help of Bayesian strategies, can offer a context for therapy individualization, but they are still limited by the absence of complete information and high intersubjective differences. Artificial intelligence (AI) can also be used to provide an extra level of support by processing vast and multifaceted data, discovering latent trends, and improving dose predictions in real time. This review concluded that applications of AI-driven tools are now emerging in neonatal intensive care, particularly for antibiotics and analgesics, where accurate dosing is critical. Combining AI with known pharmacometric practices could assist clinicians in minimizing adverse drug reactions, enhancing treatment outcomes, and getting closer to actual personalized pharmacotherapy in neonates.
- Open Access
- 12 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
A review on nanotechnology in drug delivery systems for cancer therapy
Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.
- 12 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Open AccessA review on nanotechnology in drug delivery systems for cancer therapy
Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.
- Open Access
- 25 March 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-12
Precision medicine across endocrine, metabolic, immune, and oncologic systems: an integrated mechanistic review
The pharmacological therapy of neonates is extremely complicated due to the immature organ systems of the body, high water content, and low numbers of clinical studies in children of this age. Conventional dosing strategies, usually based on weight or age, are often inaccurate and may result in either underexposure or toxicity. A structured literature search was performed in PubMed/MEDLINE and Scopus, as well as in Web of Science, from the year 2000 until September 2025. The search was based on neonatal pharmacokinetics, model-informed precision dosing (MIPD), Bayesian dosing, and artificial intelligence/machine learning. Following the removal of duplicates and 2-stage screening (title/abstract and full-text review), 82 studies were used in the end to conduct this review. This review follows the PRISMA 2020 flow selection style. We established that pharmacokinetic and pharmacodynamic (popPK/PD) models, with the help of Bayesian strategies, can offer a context of therapy individualization, but they are still limited by the absence of complete information and high intersubjective differences. Artificial intelligence (AI) can also be used to provide an extra level of support by processing vast and multifaceted data, discovering latent trends, and improving predictions of doses in real time. Our review concluded that applications of AI-driven tools are now emerging in neonatal intensive care, particularly for antibiotics and analgesics, where accurate dosing is critical. Combining AI with the known pharmacometric practices could assist clinicians to minimize adverse drug reactions, enhance treatment outcomes, and get closer to the actual personalized pharmacotherapy in neonates.
- 25 March 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-12
Open AccessPrecision medicine across endocrine, metabolic, immune, and oncologic systems: an integrated mechanistic review
The pharmacological therapy of neonates is extremely complicated due to the immature organ systems of the body, high water content, and low numbers of clinical studies in children of this age. Conventional dosing strategies, usually based on weight or age, are often inaccurate and may result in either underexposure or toxicity. A structured literature search was performed in PubMed/MEDLINE and Scopus, as well as in Web of Science, from the year 2000 until September 2025. The search was based on neonatal pharmacokinetics, model-informed precision dosing (MIPD), Bayesian dosing, and artificial intelligence/machine learning. Following the removal of duplicates and 2-stage screening (title/abstract and full-text review), 82 studies were used in the end to conduct this review. This review follows the PRISMA 2020 flow selection style. We established that pharmacokinetic and pharmacodynamic (popPK/PD) models, with the help of Bayesian strategies, can offer a context of therapy individualization, but they are still limited by the absence of complete information and high intersubjective differences. Artificial intelligence (AI) can also be used to provide an extra level of support by processing vast and multifaceted data, discovering latent trends, and improving predictions of doses in real time. Our review concluded that applications of AI-driven tools are now emerging in neonatal intensive care, particularly for antibiotics and analgesics, where accurate dosing is critical. Combining AI with the known pharmacometric practices could assist clinicians to minimize adverse drug reactions, enhance treatment outcomes, and get closer to the actual personalized pharmacotherapy in neonates.